key: cord-0868158-nn76l9iv authors: Sigler, Rachel; Aslam, Saima title: SARS‐CoV‐2 vaccine clinical efficacy in SOT: What we know and our current gaps date: 2022-02-25 journal: Transpl Infect Dis DOI: 10.1111/tid.13809 sha: 9a4eb30ea4d8f14e275dd7c7fb2741cdf5c54d89 doc_id: 868158 cord_uid: nn76l9iv COVID-19 vaccine immunogenicity is variable in immunocompromised patients and sub-optimal when compared to the general population. Clinical effectiveness data in solid organ transplant recipients (SOTR) remains scarce though points to a clinical benefit despite higher rate of breakthrough infection. Large multicenter studies should ideally assess incidence of breakthrough cases based on type of vaccination, time since vaccination, variants of concern, as well as the organ transplanted, age of the transplant recipient, and disease severity and outcomes. Sophisticated statistical modeling is needed to account for a variety of confounders. Lastly, duration of active viral replication in the setting of breakthrough infections remains unknown for immunosuppressed vaccinated patients and has implications for isolation duration and potential development of future viral variants. Despite advances in vaccination recommendations, now including additional vaccines doses, and medical prevention with new monoclonal antibodies, SOTR should continue to follow precautionary measures as new viral variants emerge. This article is protected by copyright. All rights reserved. Since the arrival of SARS-CoV-2 vaccines, solid organ transplant recipients' (SOTRs) protection from these vaccines has been under investigation. A number of studies have evaluated SOTR's adaptive immune response via measurement of spike protein IgG or receptor binding domain IgG. [1] [2] [3] [4] Rates of detectable antibody after two doses of mRNA vaccine are variable, ranging from 0%-64% 1,5,6 but are subject to interpretation and variability due to a variety of confounding factors. 7 T-cell response ranges from 5-79% in various studies and may be present despite lack of measurable antibody. 6, 8, 9 Only a few studies have assessed clinical outcomes and demonstrate reduced rate of symptomatic COVID-19 and reduced mortality. [10] [11] [12] In one single center study, there was an almost 80% reduction in risk of symptomatic COVID-19 compared to unvaccinated SOTR. 12 infection in SOTR. Case definitions were not standard and probably resulted in over-estimation of severe disease, generally defined as oxygen saturation less than 94% on room air, based on National Institutes of Health Treatment Guidelines, but in this paper was defined as any illness resulting in hospitalization. 23 Among 66 cases, 43 (65.1%) occurred more than 14 days after the second dose of mRNA vaccination (i.e., true breakthrough infections). Among these 43, 25.8% had critical illness, and 15.2% required mechanical ventilation; with associated with 7% mortality. In other series of breakthrough infections, clinical outcomes are variable, with mortality ranging from 0%-22%. 15, 24, 25 Reported disease severity has been variable as well and may be related to use of monoclonal antibodies at some centers. At our institution, two of 12 breakthrough cases required supplemental oxygen, although five of 12 were admitted with one mortality; eight patients received monoclonal antibodies. 25 The Saharia et al.'s paper is the first multicenter series detailing clinical manifestations of breakthrough COVID-19 in SOTR. However, significant bias exists both in the manner of case solicitation (in favor of hospitalized and more severe cases) and definitions of disease (again favoring more severe disease). With increasing variants of concern, in particular the Omicron variant currently, we need unbiased assessments of vaccine effectiveness and breakthrough risk in SOTR. 26 It is critical to develop a large multicenter database of breakthrough infections and to estimate incidence of breakthrough infections using clear denominators of all vaccinated SOTRs. Studies should ideally assess incidence of breakthrough cases based on type of vaccination, time since vaccination, variants of concern, as well as the organ transplanted, age of the transplant recipient, and disease severity and outcomes. Sophisticated statistical modeling is needed to account for a variety of confounding factors including the ebb and flow of the pandemic itself, survival bias, differing times of vaccination, and accurate case ascertainment. These studies will only be possible with large registry-based data collection. As we move forward with additional recommended vaccine doses, the definition of a "fully vaccinated" SOTR will need to be updated as well. 9, 27 Lastly, duration of active viral replication in the setting of breakthrough infections remains unknown for immunosuppressed vaccinated patients and has implications for isolation duration and potential development of future viral variants; in particular short isolation periods may be insufficient. As the pandemic continues to evolve, it is increasingly clear that our current vaccination strategy is not the only path for infection prevention in vulnerable patients, and additional strategies are needed. There are ongoing clinical trials that are investigating breakthrough COVID- Antibody response to 2-Dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus Safety and immunogenicity of anti-SARS-CoV-2 messenger RNA vaccines in recipients of solid organ transplants Poor anti-SARS-CoV-2 humoral and T-cell responses after 2 injections of mRNA vaccine in kidney transplant recipients treated with belatacept Immunogenicity of BNT162b2 mRNA COVID-19 vaccine and SARS-CoV-2 infection in lung transplant recipients Third dose of the BNT162b2 vaccine in heart transplant recipients: immunogenicity and clinical experience Cellular and humoral immune response after mRNA-1273 SARS-CoV-2 vaccine in liver and heart transplant recipients Humoral and cellular immune response and safety of two-dose SARS-CoV-2 mRNA-1273 vaccine in solid organ transplant recipients Two doses of SARS-CoV-2 vaccines reduce risk of death due to COVID-19 in solid organ transplant recipients: preliminary outcomes from a UK registry linkage analysis Real-world effectiveness of the Pfizer-BioNTech BNT162b2 and Oxford-AstraZeneca ChAdOx1-S vaccines against SARS-CoV-2 in solid organ and islet transplant recipients COVID-19 vaccination is protective of clinical disease in solid organ transplant recipients Risk of breakthrough SARS-CoV-2 infections in adult transplant recipients Effectiveness of SARS-CoV-2 vaccination in fully vaccinated solid organ transplant recipients Early experience with SARs-CoV-2 mRNA vaccine breakthrough among kidney transplant recipients Preemptive antibody therapy for vaccine breakthrough SARS-CoV-2 infection in immunocompromised patients Breakthrough COVID-19 infections after mRNA vaccination in solid organ transplant recipients in Miami Clinically significant COVID-19 following SARS-CoV-2 vaccination in kidney transplant recipients Occurrence of severe COVID-19 in vaccinated transplant patients Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study BNT162b2 vaccine booster and mortality due to Covid-19 Protection of BNT162b2 vaccine booster against Covid-19 in Israel Coronavirus disease 2019 (COVID-19) treatment guidelines. National Institutes of Health Severe consequences of COVID-19 infection among vaccinated kidney transplant recipients COVID-19 vaccination is protective of clinical disease in solid organ transplant recipients. Transplant Infect Dis CDC. Science brief: Omicron (b.1.1.529) variant. 2021. Accessed Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients AstraZeneca AZD7442 PROVENT phase III prophylaxis trial met primary endpoint in preventing COVID-19 Early Remdesivir to prevent progression to severe Covid-19 in outpatients Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. EPIC-HR Investigators